| Community Medical Associates, Inc. | |
|
25 Marston St Ste 301 Lawrence MA 01841-2358 | |
| (978) 683-4000 | |
| (978) 946-8136 |
| Full Name | Community Medical Associates, Inc. |
|---|---|
| Speciality | Family Medicine |
| Location | 25 Marston St Ste 301, Lawrence, Massachusetts |
| Authorized Official Name and Position | Abha Agrawal (CEO) |
| Authorized Official Contact | 9789468094 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Community Medical Associates, Inc. 25 Marston St Ste 301 Lawrence MA 01841-2358 Ph: (978) 683-4000 | Community Medical Associates, Inc. 25 Marston St Ste 301 Lawrence MA 01841-2358 Ph: (978) 683-4000 |
| NPI Number | 1144544040 |
|---|---|
| Provider Enumeration Date | 03/22/2010 |
| Last Update Date | 04/24/2024 |
| Medicare PECOS PAC ID | 6002946928 |
|---|---|
| Medicare Enrollment ID | O20100618000560 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144544040 | NPI | - | NPPES |
| 110085229A | Medicaid | MA |
| Provider Name | Patricia A Scala |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1760442230 PECOS PAC ID: 7315995818 Enrollment ID: I20050111001016 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | David E. Gossman |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1962508796 PECOS PAC ID: 9133194186 Enrollment ID: I20050330000979 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Nancy C Landay |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1063446862 PECOS PAC ID: 2860424546 Enrollment ID: I20050901000712 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Sunit Mukherjee |
|---|---|
| Provider Type | Practitioner - Interventional Cardiology |
| Provider Identifiers | NPI Number: 1356335327 PECOS PAC ID: 3476598533 Enrollment ID: I20060509000308 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | James W Meyer |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1356473839 PECOS PAC ID: 3779676903 Enrollment ID: I20070905000095 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Sanjay Gupta |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1801803523 PECOS PAC ID: 6608870225 Enrollment ID: I20120417000535 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Earl R Gonzales |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1215134390 PECOS PAC ID: 9032366349 Enrollment ID: I20120821000935 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Garo H Garabedian |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1962890038 PECOS PAC ID: 2466762224 Enrollment ID: I20151106000065 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Torkom A Garabedian |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1063852127 PECOS PAC ID: 9032407341 Enrollment ID: I20161019000497 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Sahar Chitgar |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1780993311 PECOS PAC ID: 5799929022 Enrollment ID: I20170419000988 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Josefina Medina |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518442201 PECOS PAC ID: 3870839574 Enrollment ID: I20190117001604 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Melissa M Gurney |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1699328062 PECOS PAC ID: 8123457116 Enrollment ID: I20200326000164 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Kristen L Barrett |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427603851 PECOS PAC ID: 9436578101 Enrollment ID: I20200929002999 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Nicole J Friel |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053932343 PECOS PAC ID: 0345650032 Enrollment ID: I20201109002064 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Elie I Ata |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1659801520 PECOS PAC ID: 5193095578 Enrollment ID: I20210616000069 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Jamie E Ellis |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1891225561 PECOS PAC ID: 8022389204 Enrollment ID: I20210621003149 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Isabel M Bernal |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1548614704 PECOS PAC ID: 4183910466 Enrollment ID: I20220714001279 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Suhaiti L Villa |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376144741 PECOS PAC ID: 5597137356 Enrollment ID: I20230206000413 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Allison Madore |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1508450826 PECOS PAC ID: 0941663454 Enrollment ID: I20230831001647 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Kaitlan J Ahrens |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1073976650 PECOS PAC ID: 4688968464 Enrollment ID: I20230918002934 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Syed Abbas |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1154611929 PECOS PAC ID: 9638420235 Enrollment ID: I20230918003657 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
| Provider Name | Stella Athanasopoulos |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1811506397 PECOS PAC ID: 1850755232 Enrollment ID: I20230919001120 |
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
News Archive
Thanks to advanced medical treatments, women diagnosed with breast cancer today will likely survive the disease.
Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.
Urinary tract infections are common in women, costing an estimated $2.5 billion per year to treat in 2000 in the United States alone. These infections frequently recur, affecting 2 to 3 percent of all women.
Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden.
› Verified 9 days ago
Merrimack Medical & Walk In Center Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 25 Marston St, Ste 304, Lawrence, MA 01841 Phone: 978-688-3100 Fax: 978-688-3133 | |
Greater Lawrence Family Health Center, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1 General St, Lamprey Building, 4th Floor, Lawrence, MA 01841 Phone: 978-983-0488 | |
Ez Med Services Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 225 Essex Street, Suite 1b, Lawrence, MA 01841 Phone: 857-246-1983 | |
Elder Services Of The Merrimack Valley, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 280 Merrimack St, Suite 400, Lawrence, MA 01843 Phone: 978-683-7747 Fax: 978-687-1067 | |
Mmwic Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 25 Marston St, 3rd Floor, Lawrence, MA 01841 Phone: 978-688-3100 | |
Lawrence G. Kidd M.d., P.c. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 25 Marston St, Ste 401, Lawrence, MA 01841 Phone: 978-682-3686 Fax: 978-794-0841 |